Medarex, Inc. (NASDAQ: MEDX) announced that its wholly owned MDX-1100 met its primary endpoints for patients receiving methotrexate in a Phase II ‘proof of concept’ trial in patients with active rheumatoid arthritis.  The trial indicated that three-times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks when compared to placebo.   So far we have shares indicated 3% higher on the news.

Read the full story at BioHealthInvestor.com.